Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects

The Lancet Neurology

Volumn 15, Issue 7, 2016, Pages 736-747

  Benedetti, Fabrizio ^a,b,c   Carlino, Elisa ^a   Piedimonte, Alessandro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Plateau Ros   (Italy)

^c NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

BIOLOGICAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE EXACERBATION; DRUG MECHANISM; GENOTYPE; HAWTHORNE EFFECT; HUMAN; MEDICAL PRACTICE; NOCEBO EFFECT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; REVIEW; SOCIAL INTERACTION; SOCIAL PHOBIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNCERTAINTY; BRAIN DISEASES; METHODOLOGY; OUTCOME ASSESSMENT; STANDARDS;

BRAIN DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; RESEARCH DESIGN;

EID: 84963951583     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00066-1     Document Type: Review

References (89)

1. Benedetti, F, Placebo and the new physiology of the doctor-patient relationship. Physiol Rev 93 (2013), 1207–1246.
2. Kirsch, I, Response expectancy as determinant of experience and behavior. Am Psychologist 40 (1985), 1189–1202.
3. Colloca, L, Benedetti, F, Placebos and painkillers: is mind as real as matter?. Nat Rev Neurosci 6 (2005), 545–552.
4. McCambridge, J, Witton, J, Elbourne, DR, Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 67 (2014), 267–277.
5. Benedetti, F, Amanzio, M, Maggi, G, Potentiation of placebo analgesia by proglumide. Lancet, 346, 1995, 1231.
6. Bingel, U, Wanigasekera, V, Wiech, K, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med, 3, 2011, 70ra14.
7. Gollub, RL, Kong, J, For placebo effects in medicine, seeing is believing. Sci Transl Med, 3, 2011, 70ps5.
8. Benedetti, F, Amanzio, M, Rosato, R, Blanchard, C, Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med 17 (2011), 1228–1230.
9. De la Fuente-Fernández, R, Ruth, TJ, Sossi, V, Schulzer, M, Calne, DB, Stoessl, AJ, Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 (2001), 1164–1166.
10. Petrovic, P, Kalso, E, Petersson, KM, Ingvar, M, Placebo and opioid analgesia—imaging a shared neuronal network. Science 295 (2002), 1737–1740.
11. Wager, TD, Scott, DJ, Zubieta, J-K, Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci USA 104 (2007), 11056–11061.
12. Eippert, F, Bingel, U, Schoell, ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63 (2009), 533–543.
13. Carlino, E, Frisaldi, E, Benedetti, F, Pain and the context. Nat Rev Rheumatol 10 (2014), 348–355.
14. Colloca, L, Lopiano, L, Lanotte, M, Benedetti, F, Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 3 (2004), 679–684.
15. Benedetti, F, Carlino, E, Pollo, A, Hidden administration of drugs. Clin Pharmacol Ther 90 (2011), 651–661.
16. Benedetti, F, Drugs and placebos: what's the difference?: Understanding the molecular basis of the placebo effect could help clinicians to better use it in clinical practice. EMBO Rep 15 (2014), 329–332.
17. Atlas, LY, Whittington, RA, Lindquist, MA, Wielgosz, J, Sonty, N, Wager, TD, Dissociable influences of opiates and expectations on pain. J Neurosci 32 (2012), 8053–8064.
18. Vase, L, Amanzio, M, Price, DD, Nocebo vs. placebo: the challenges of trial design in analgesia research. Clin Pharmacol Ther 97 (2015), 143–150.
19. Amanzio, M, Corazzini, LL, Vase, L, Benedetti, F, A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146 (2009), 261–269.
20. Rief, W, Nestoriuc, Y, von Lilienfeld-Toal, A, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 32 (2009), 1041–1056.
21. Mora, MS, Nestoriuc, Y, Rief, W, Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci 366 (2011), 1879–1888.
22. Mitsikostas, DD, Mantonakis, LI, Chalarakis, NG, Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31 (2011), 550–561.
23. Mitsikostas, DD, Chalarakis, NG, Mantonakis, LI, Delicha, E-M, Sfikakis, PP, Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 19 (2012), 672–680.
24. Häuser, W, Bartram, C, Bartram-Wunn, E, Tölle, T, Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain 28 (2012), 437–451.
25. Papadopoulos, D, Mitsikostas, DD, A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 259 (2012), 436–447.
26. Benedetti, F, Placebo effects: from the neurobiological paradigm to translational implications. Neuron 84 (2014), 623–637.
27. Wiffen, PJ, Derry, S, Moore, RA, Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev, 12, 2013 CD006044.
28. Wiffen, PJ, Derry, S, Moore, RA, Lunn, MPT, Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev, 7, 2014 CD010943.
29. Hearn, L, Derry, S, Moore, RA, Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev, 2, 2012 CD009318.
30. Simpson, DM, Schifitto, G, Clifford, DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74 (2010), 413–420.
31. Dolgin, E, Fluctuating baseline pain implicated in failure of clinical trials. Nat Med, 16, 2010, 1053.
32. Bartfai, T, Lees, GV, Pharma TARP: a troubled asset relief program for novel, abandoned projects in the pharmaceutical industry. SciWorld J 11 (2011), 454–457.
33. Katz, J, Finnerup, NB, Dworkin, RH, Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 70 (2008), 263–272.
34. Tuttle, AH, Tohyama, S, Ramsay, T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 156 (2015), 2616–2626.
35. Walsh, BT, Seidman, SN, Sysko, R, Gould, M, Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002), 1840–1847.
36. Dworkin, RH, Katz, J, Gitlin, MJ, Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology 65 (2005), S7–19.
37. Khan, A, Warner, HA, Brown, WA, Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57 (2000), 311–317.
38. Andrews, G, Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry 178 (2001), 192–194.
39. Kirsch, I, Sapirstein, G, Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment, 1, 1998, 0002a.
40. Alphs, L, Benedetti, F, Fleischhacker, WW, Kane, JM, Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?. Int J Neuropsychopharmacol 15 (2012), 1003–1014.
41. Kemp, AS, Schooler, NR, Kalali, AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr Bull 36 (2010), 504–509.
42. Chen, Y-F, Wang, S-J, Khin, NA, Hung, HMJ, Laughren, TP, Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 9 (2010), 217–229.
43. Papadopoulos, D, Mitsikostas, DD, Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 16 (2010), 816–828.
44. Shetty, N, Friedman, JH, Kieburtz, K, Marshall, FJ, Oakes, D, The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 22 (1999), 207–212.
45. Goetz, CG, Leurgans, S, Raman, R, Stebbins, GT, Objective changes in motor function during placebo treatment in PD. Neurology 54 (2000), 710–714.
46. Goetz, CG, Laska, E, Hicking, C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 23 (2008), 700–707.
47. Goetz, CG, Wuu, J, McDermott, MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 23 (2008), 690–699.
48. Watts, RL, Freeman, TB, Hauser, RA, et al. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of stereotaxic intrastriatal implantation of fetal porcine ventral mesencephalic tissue (Neurocell-PD) vs imitation surgery in patients with Parkinson disease (PD). Parkinsonism Relat Disord, 7, 2001, S87.
49. Olanow, CW, Goetz, CG, Kordower, JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003), 403–414.
50. Bartus, RT, Weinberg, MS, Samulski, RJ, Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 22 (2014), 487–497.
51. LeWitt, PA, Rezai, AR, Leehey, MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomized trial. Lancet Neurol 10 (2011), 309–319.
52. Christine, CW, Starr, PA, Larson, PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73 (2009), 1662–1669.
53. Muramatsu, S, Fujimoto, K, Kato, S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18 (2010), 1731–1735.
54. Bartus, RT, Baumann, TL, Siffert, J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80 (2013), 1698–1701.
55. McRae, C, Cherin, E, Yamazaki, TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 61 (2004), 412–420.
56. Bausell, RB, Lao, L, Bergman, S, Lee, W-L, Berman, BM, Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials. Eval Health Prof 28 (2005), 9–26.
57. Linde, K, Witt, CM, Streng, A, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 128 (2007), 264–271.
58. Younger, J, Gandhi, V, Hubbard, E, Mackey, S, Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials 9 (2012), 767–776.
59. Solomon, RL, An extension of control group design. Psychol Bull 46 (1949), 137–150.
60. McCambridge, J, Kypri, K, Elbourne, DR, A surgical safety checklist. N Engl J Med 360 (2009), 2373–2374.
61. Cizza, G, Piaggi, P, Rother, KI, Csako, G, Sleep Extension Study Group. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS One, 9, 2014, e104176.
62. Lorber, W, Mazzoni, G, Kirsch, I, Illness by suggestion: expectancy, modeling, and gender in the production of psychosomatic symptoms. Ann Behav Med 33 (2007), 112–116.
63. Hunter, T, Siess, F, Colloca, L, Socially induced placebo analgesia: a comparison of a pre-recorded versus live face-to-face observation. Eur J Pain 18 (2014), 914–922.
64. Valentini, E, Martini, M, Lee, M, Aglioti, SM, Iannetti, GD, Seeing facial expressions enhances placebo analgesia. Pain 155 (2014), 666–673.
65. Colloca, L, Benedetti, F, Placebo analgesia induced by social observational learning. Pain 144 (2009), 28–34.
66. Swider, K, Bąbel, P, The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning. Pain 154 (2013), 1312–1317.
67. Vögtle, E, Barke, A, Kröner-Herwig, B, Nocebo hyperalgesia induced by social observational learning. Pain 154 (2013), 1427–1433.
68. Benedetti, F, Durando, J, Vighetti, S, Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway. Pain 155 (2014), 921–928.
69. Rief, W, Bingel, U, Schedlowski, M, Enck, P, Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 90 (2011), 722–726.
70. Enck, P, Bingel, U, Schedlowski, M, Rief, W, The placebo response in medicine: minimize, maximize or personalize?. Nat Rev Drug Discov 12 (2013), 191–204.
71. Vase, L, Amanzio, M, Price, DD, Nocebo vs. placebo: the challenges of trial design in analgesia research. Clin Pharmacol Ther 97 (2015), 143–150.
72. Fava, M, Evins, AE, Dorer, DJ, Schoenfeld, DA, The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72 (2003), 115–127.
73. Fava, M, Mischoulon, D, Iosifescu, D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81 (2012), 87–97.
74. Hall, KT, Loscalzo, J, Kaptchuk, TJ, Genetics and the placebo effect: the placebome. Trends Mol Med 21 (2015), 285–294.
75. Colagiuri, B, Schenk, LA, Kessler, MD, Dorsey, SG, Colloca, L, The placebo effect: from concepts to genes. Neuroscience 307 (2015), 171–190.
76. Furmark, T, Appel, L, Henningsson, S, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 28 (2008), 13066–13074.
77. Leuchter, AF, McCracken, JT, Hunter, AM, Cook, IA, Alpert, JE, Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 29 (2009), 372–377.
78. Hall, KT, Lembo, AJ, Kirsch, I, et al. Catechol-o-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One, 7, 2012, e48135.
79. Peciña, M, Martínez-Jauand, M, Hodgkinson, C, Stohler, CS, Goldman, D, Zubieta, JK, FAAH selectively influences placebo effects. Mol Psychiatry 19 (2014), 385–391.
80. Benedetti, F, Frisaldi, E, Creating placebo responders and non-responders in the laboratory: boons and banes. Pain Manag 4 (2014), 165–167.
81. Faries, DE, Heiligenstein, JH, Tollefson, GD, Potter, WZ, The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J ClinPsychopharmacol 21 (2001), 561–568.
82. Revicki, DA, Frank, L, Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 15 (1999), 423–434.
83. Fritz, JM, Cleland, J, Effectiveness versus efficacy: more than a debate over language. J Orthop Sports Phys Ther 33 (2003), 163–165.
84. Singal, AG, Higgins, PDR, Waljee, AK, A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol, 5, 2014, e45.
85. Kong, J1, Spaeth, R, Cook, A, et al. Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. PLoS One, 8, 2013, e67485.
86. Benedetti, F, Dogue, S, Different placebos, different mechanisms, different outcomes: lessons for clinical trials. PLoS One, 10, 2015, e0140967.
87. Benedetti, F, The patient's brain: the neuroscience behind the doctor-patient relationship, 2010, Oxford University Press, Oxford.
88. Benedetti, F, Placebo effects, 2nd edn., 2014, Oxford University Press, Oxford.
89. Kaptchuk, TJ, Miller, FG, Placebo effects in medicine. N Engl J Med 373 (2015), 8–9.